ArticleThe Journal of infectious diseases2026
Investigation of Correlates of Protection Against Gonococcal Infection by Comparative Immunoprofiling of Responses in Experimental and Clinical Studies.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeisseria gonorrhoeae is a major sexually transmitted pathogen with rising antimicrobial resistance. Epidemiological studies suggest meningococcal outer membrane vesicle (OMV) vaccines, eg 4CMenB (Bexsero), offer partial cross-protection, but immune correlates remain undefined.
methodsUsing a murine genital tract infection model, we compared systemic and mucosal responses after immunization with Bexsero, gonococcal OMVs (Ng OMVs) with alum, or alum alone. Vaccinated mice were challenged intravaginally with N. gonorrhoeae. Serum bactericidal activity (SBA) was measured, and antigen-specific IgG responses were profiled using gonococcal protein microarrays. Murine responses were compared with high-risk Bexsero-immunized humans and patients with gonococcal infection.
resultsBexsero significantly accelerated bacterial clearance compared with Ng OMV or alum. Serum and vaginal IgG profiles were highly correlated, revealing distinct antigenic signatures between groups. Bexsero elicited responses to gonococcal orthologs of its recombinant antigens (GNA1030, GNA2091, NHBA), whereas Ng OMVs induced Opa, PilQ, and MtrE responses. SBA did not correlate with clearance; however, early PMN influx was associated with reduced bacterial load. Antigen-specific IgG patterns were concordant between Bexsero-immunized mice and humans.
conclusionsProtein microarrays with multivariate analysis identified antibody signatures associated with protection, supporting the translational value of this model for defining correlates of protection and guiding gonococcal vaccine development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.